Blueprint Investment Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-899
Closed -$234K 103
2024
Q4
$234K Sell
899
-731
-45% -$217K 0.04% 179
2024
Q3
$525K Sell
1,630
-554
-25% -$181K 0.1% 104
2024
Q2
$683K Buy
2,184
+485
+29% +$142K 0.15% 65
2024
Q1
$483K Sell
1,699
-437
-20% -$128K 0.1% 81
2023
Q4
$615K Sell
2,136
-131
-6% -$35.7K 0.17% 63
2023
Q3
$609K Buy
+2,267
New +$566K 0.2% 59
2023
Q1
Sell
-5,330
Closed -$1.4M 235
2022
Q4
$1.4M Buy
5,330
+2,482
+87% +$665K 0.3% 69
2022
Q3
$642K Sell
2,848
-1,869
-40% -$453K 0.18% 71
2022
Q2
$1.15M Buy
4,717
+1,939
+70% +$475K 0.31% 54
2022
Q1
$672K Buy
2,778
+1,487
+115% +$342K 0.17% 86
2021
Q4
$290K Buy
+1,291
New +$272K 0.07% 159
2021
Q2
Sell
-1,053
Closed -$262K 77
2021
Q1
$262K Buy
+1,053
New +$251K 0.2% 56

Other funds holding AMGN

Blueprint Investment Partners's AMGN Position: Q1 2025 in Review

Blueprint Investment Partners sold out of Amgen (AMGN) in Q1 2025, closing a stake of 899 shares — an estimated $234K sold.

Blueprint Investment Partners first reported a position in AMGN in Q1 2021 and held it in 12 quarters. The position peaked at $1.4M in Q4 2022. 2,926 funds tracked by Wall St. Rank hold AMGN as of Q1 2025.

  • Blueprint Investment Partners reported no remaining Amgen position as of Q1 2025 after selling out during the quarter.
  • Blueprint Investment Partners sold 899 Amgen shares in Q1 2025, an estimated $234K.
  • Blueprint Investment Partners first reported a position in Amgen in Q1 2021 and held it in 12 quarters.
  • Blueprint Investment Partners's Amgen position peaked at $1.4M in Q4 2022.
  • 2,926 funds tracked by Wall St. Rank held Amgen as of Q1 2025.

Based on Blueprint Investment Partners's 13F filing for Q1 2025, filed 12 May 2025.